Market

Diagnostic Assays: Seegene and QIAGEN collaborate

Seegene Inc. today announced that it has entered into a worldwide collaboration agreement with QIAGEN N.V. to develop and supply molecular diagnostic assays.

Thierry Bernard, Senior Vice President, Molecular Diagnostics Business Area.
Thierry Bernard, Senior Vice President, Molecular Diagnostics Business Area.
Source: QIAGEN

Under the terms of the agreement, Seegene will develop and manufacture multiplex infectious disease testing panels exclusively designed for QIAGEN's real-time PCR cycler Rotor-Gene Q, member of QIAGEN's QIAsymphony family of automated instruments, and QIAGEN will have worldwide commercialization rights to these tests.
 
Seegene's Founder and CEO, Dr. Jong-Yoon Chun, added, "This is an exciting partnership that will deliver a very powerful tool providinga more comprehensive and actionable diagnosis to clinicians worldwide.  QIAGEN's IVD market leadership will also help to further grow our multiplex real-time PCR diagnostic testing footprint in disease indications that are in need of powerful new diagnostics."
 
Seegene expends tremendous effort to continually develop and commercialize innovative high-multiplex PCR chemistry technologies that enable more accurate and cost-effective molecular diagnostics. MuDT™ technology is the perfection of qPCR technology by simultaneously identifying and quantifying multiple targets in a single fluorescence channel, without melting curve analysis after amplification.
 
"We are very pleased to partner with Seegene and incorporate their novel and innovative proprietary technologies into our sample to insight offering for molecular diagnostic customers," said Thierry Bernard,Senior Vice President, Head of the Molecular Diagnostics Business Area and a member of the Executive Committee of QIAGEN.  "With Seegene's multiplex reagents enabling simultaneous and multiple detection and quantification of various target genes, QIAGEN is further broadening the menu of our QIAsymphony platform and increasing its leadership in the molecular diagnostics market."
 
This is the second major global original design manufacturing (ODM) deal that Seegene has entered into. In November 2014, Seegene and Beckman Coulter inked a deal under which Seegene will manufacture reagents designed exclusively for Beckman Coulter's new Veris MDx sample-to-answer molecular diagnostics system.


Source: QIAGEN and Seegene

14.07.2015

Read all latest stories

Related articles

Photo

News • Rapid detection

Molecular diagnostic test for Covid-19, Flu, RSV receives CE mark

A new rapid molecular diagnostic test from Cepheid has received the CE mark for distribution in the European market. The test, called Xpert Xpress CoV-2/Flu/RSV plus, is designed for qualitative…

Photo

News • Infection

Siemens Zika test receives FDA emergency use authorization

The U.S. Food and Drug Administration (FDA) has granted Siemens Healthcare Diagnostics Inc. (Siemens) an Emergency Use Authorization (EUA) for its real-time PCR Zika Virus assay, the VERSANT® Zika…

Photo

News • ECCMID 2015

Curetis launches next-generation pneumonia application

Curetis AG, a developer of next-level molecular diagnostic solutions, announced the successful completion of the clinical and analytical CE performance evaluation of its next-generation Unyvero P55…

Related products

Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter Diagnostics
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Beckman Coulter – Psychiatry Antipsychotic Assays

Clinical Chemistry

Beckman Coulter – Psychiatry Antipsychotic Assays

Beckman Coulter Diagnostics
DRG Instruments – DRG:Hybrid-XL

Immunochemistry

DRG Instruments – DRG:Hybrid-XL

DRG Instruments GmbH
Subscribe to Newsletter